The increasing resistance of the disease-causing pathogens to antimicrobial drugs is a public
health concern and a socio-economic burden. The emergence of multi-drug resistant strains has
made it harder to treat and combat infectious diseases with available conventional antibiotics. There
are currently few effective therapeutic regimens for the successful prevention of infections caused by
drug-resistant microbes. Various alternative strategies used in the recent past to decrease and limit antibiotic
resistance in pathogens include bacteriophages, vaccines, anti-biofilm peptides, and antimicrobial
peptides. However, in this review, we focus on the novel and robust molecular approach of antisense
RNA (asRNA) technology and the clustered regulatory interspaced short palindromic repeat
(CRISPR)-based antibiotic therapy, which can be exploited to selectively eradicate the drug-resistant
bacterial strain in a sequence-specific fashion establishing opportunities in the treatment of multi-drug
resistant related infections.
Keywords: Drug-resistant bacteria, antisense RNA technology, CRISPR-based antibiotic therapy, microbes, MDR, AMR.
Rights & PermissionsPrintExport